omeprazole has been researched along with Liver Failure, Acute in 2 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Liver Failure, Acute: A form of rapid-onset LIVER FAILURE, also known as fulminant hepatic failure, caused by severe liver injury or massive loss of HEPATOCYTES. It is characterized by sudden development of liver dysfunction and JAUNDICE. Acute liver failure may progress to exhibit cerebral dysfunction even HEPATIC COMA depending on the etiology that includes hepatic ISCHEMIA, drug toxicity, malignant infiltration, and viral hepatitis such as post-transfusion HEPATITIS B and HEPATITIS C.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Omeprazole (OMZ) is a proton pump inhibitor that is used to reduce gastric acid secretion, but little is known about its possible liver protective effects." | 5.72 | Omeprazole Increases Survival Through the Inhibition of Inflammatory Mediaters in Two Rat Sepsis Models. ( Hashimoto, Y; Hatta, M; Kaibori, M; Kotsuka, M; Nakatake, R; Nishizawa, M; Okumura, T; Okuyama, T; Sekimoto, M; Yoshida, T, 2022) |
| "Omeprazole (OMZ) is a proton pump inhibitor that is used to reduce gastric acid secretion, but little is known about its possible liver protective effects." | 1.72 | Omeprazole Increases Survival Through the Inhibition of Inflammatory Mediaters in Two Rat Sepsis Models. ( Hashimoto, Y; Hatta, M; Kaibori, M; Kotsuka, M; Nakatake, R; Nishizawa, M; Okumura, T; Okuyama, T; Sekimoto, M; Yoshida, T, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kotsuka, M | 1 |
| Hashimoto, Y | 1 |
| Nakatake, R | 1 |
| Okuyama, T | 1 |
| Hatta, M | 1 |
| Yoshida, T | 1 |
| Okumura, T | 1 |
| Nishizawa, M | 1 |
| Kaibori, M | 1 |
| Sekimoto, M | 1 |
| Yusoff, IF | 1 |
| Nairn, P | 1 |
| Morgan, CA | 1 |
2 other studies available for omeprazole and Liver Failure, Acute
| Article | Year |
|---|---|
Omeprazole Increases Survival Through the Inhibition of Inflammatory Mediaters in Two Rat Sepsis Models.
Topics: Animals; Cell Culture Techniques; Disease Models, Animal; Galactosamine; Hepatectomy; Hepatocytes; I | 2022 |
Multiple organ failure related to pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acidosis, Lactic; Acute Kidney Injury; Aged; Anti-Ulcer Age | 1999 |